Accessibility Menu
Affimed Stock Quote

Affimed (OTC: AFMD)

$0.00
(0.0%)
+0.00
Price as of October 21, 2025, 11:41 a.m. ET

KEY DATA POINTS

Current Price
$0
Daily Change
(0.0%) +$0.00
Day's Range
$0 - $0.01
Previous Close
$0
Open
$0
Beta
929.61
Volume
5,372
Average Volume
20,906
Market Cap
1.5K
Market Cap / Employee
$0.00M
52wk Range
$0 - $4.04
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$4.94
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Affimed Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
AFMD-100%-100%-92.12%-100%
S&P+15.06%+95.03%+14.29%+239%

Affimed Company Info

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

News & Analysis

Financial Health

General

Q3 2024YOY Change
Revenue$0.17M0.0%
Market Cap$51.16M0.0%
Market Cap / Employee$0.66M0.0%
Employees780.0%
Net Income-$16.63M0.0%
EBITDA-$15.23M0.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2024YOY Change
Net Cash$8.26M0.0%
Inventory00.0%

Liabilities

Q3 2024YOY Change
Long Term Debt$6.68M0.0%
Short Term Debt$7.70M0.0%

Ratios

Q3 2024YOY Change
Return On Assets-88.07%0.0%
Return On Invested Capital-74.43%0.0%

Cash Flow

Q3 2024YOY Change
Free Cash Flow-$13.13M0.0%
Operating Free Cash Flow-$13.12M0.0%

Valuation

MetricQ4 2023Q1 2024Q2 2024Q3 2024YoY Change
Price to Book1.151.241.891.71-
Price to Sales10.5018.8328.6357.04-
Price to Tangible Book Value11.541.251.891.71-
Enterprise Value to EBITDA-1.38-2.36-3.80-2.73-
Return on Equity-100.9%-112.4%-123.5%-151.5%-
Total Debt$21.38M$17.36M$15.56M$14.38M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.